$2.48
Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Overview
52-week range
$0.93
$3.23
67% of range
Avg surprise (last 3)
+15.1%
Avg reaction (last 2)
-5.7%
0% positive
Latest IV / EM
387%
EM ±60.5% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.25 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.26 | $-0.29 | +10.3% | +18.8% | -4.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.27 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.29 | $-0.35 | +17.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.32 | $-0.39 | +17.9% | — | -6.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.40 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.33 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.47 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.54 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.19 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $1M | — | $2M | $2M | $2M | — | $3M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-31M | $-33M | — | $-35M | $-37M | $-41M | — | $-52M |
| Net income | $-30M | $-31M | — | $-32M | $-34M | $-38M | — | $-48M |
| EPS (diluted) | $-0.25 | $-0.26 | — | $-0.27 | $-0.29 | $-0.32 | — | $-0.40 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32M | $40M | $47M | $41M | $41M | $45M | $36M | $38M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $158M | $180M | $209M | $221M | $230M | $248M | $292M | $310M |
| Total assets | $260M | $285M | $319M | $344M | $372M | $399M | $441M | $495M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $153M | $180M | $207M | $234M | $261M | $288M | $319M | $362M |